Intensive glucose control improves CVD risk factors

Intensive glucose control improves CVD risk factors
Intensive glucose-lowering therapy is associated with favorable changes in lipoprotein levels and inflammatory risk factors even though it does not lower the incidence of cardiovascular events, according to a study published online March 27 in Diabetes Care.

(HealthDay)—Intensive glucose-lowering therapy (INT) is associated with favorable changes in lipoprotein levels and inflammatory risk factors even though it does not lower the incidence of cardiovascular events, according to a study published online March 27 in Diabetes Care.

Juraj Koska, M.D., from the Phoenix Veterans Affairs Health Care System, and colleagues analyzed standard plasma lipids, cholesterol content of lipoprotein subfractions, and plasma inflammatory and prothrombotic markers in 266 participants of the Veterans Affairs Diabetes Trial. Measurements were taken at baseline and following nine months of either INT or standard therapy.

The researchers found that INT significantly lowered glycated hemoglobin compared to standard treatment (median reduction 2 percent versus 0.7 percent, respectively). INT also significantly increased BMI (4 versus 1 percent), total HDL (9 versus 4 percent), HDL2 (14 versus 0 percent), LDL2 (36 versus 1 percent), and plasma adiponectin (130 versus 80 percent). There were also significant reductions in triglycerides (213 versus 24 percent) and small, dense LDL4 (239 versus 213 percent). INT had no effect on levels of plasma apolipoproteins B-100 and B-48, C-reactive protein, interleukin-6, lipoprotein-associated phospholipase A2, myeloperoxidase, , and plasminogen activator inhibitor 1. Baseline interleukin-6 (hazard ratio per each quartile increase, 1.33), total LDL (1.25), apolipoprotein B-100 (1.29), and fibrinogen (1.26) were associated with incident macrovascular events but not changes in any at 9 months

"INT was associated with improved adiponectin, , and a favorable shift in LDL and HDL subfractions after nine months," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Clopidogrel after MI less effective in diabetes patients

Sep 05, 2012

(HealthDay)—Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue ...

Exercise stimulates adiponectin, raises HDL levels

Oct 18, 2012

(HealthDay)—Intensive lifestyle intervention for weight loss (ILI) significantly improves high-density lipoprotein cholesterol (HDL-C) levels in overweight and obese individuals with type 2 diabetes, which ...

Peer coaching model beneficial for patients with diabetes

Apr 03, 2013

(HealthDay)—Health coaching by peers is associated with a significant reduction in hemoglobin A1c (HbA1c) levels among patients treated in public health clinics, according to research published in the March/April ...

Recommended for you

Blood glucose levels set for achieving HbA1c targets

Apr 11, 2014

(HealthDay)—The average self-monitored blood glucose (SMBG) concentrations needed at premeal, postmeal, and bedtime have been established to achieve a range of hemoglobin A1c (HbA1c) targets, according ...

Women with diabetes less likely to have a mammogram

Apr 11, 2014

Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's ...

Nonalcoholic fatty liver disease linked to CKD in T1DM

Apr 09, 2014

(HealthDay)—For patients with type 1 diabetes, nonalcoholic fatty liver disease (NAFLD) is independently associated with the risk of incident chronic kidney disease (CKD), according to a study published ...

Common diabetes treatment could extend hypoglycaemia

Apr 08, 2014

(Medical Xpress)—Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycaemia, which ...

User comments